Aclaris reports positive phase 1 trial results for ATI-052 antibody

April 28, 2026 6:30 AM

Aclaris Therapeutics Inc. (NASDAQ: ACRS) announced positive results from a phase 1a clinical trial of ATI-052, an experimental bispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found